CM
ADVM

Crestline Management’s Adverum Biotechnologies ADVM Stock Holding History

Crestline Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,485
Closed -$78K – 204
2022
Q2 		$78K Sell
6,485
-84
-1% -$880 0.01% 214
2022
Q1 		$86K Buy
+6,569
New +$96.1K 0.01% 250

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crestline Management's ADVM Position: Q3 2022 in Review

Crestline Management sold out of Adverum Biotechnologies (ADVM) in Q3 2022, closing a stake of 6,485 shares — an estimated $78K sold.

Crestline Management first reported a position in ADVM in Q1 2022 and held it in 2 quarters. The position peaked at $86K in Q1 2022. 78 funds tracked by Wall St. Rank hold ADVM as of Q3 2022.

  • Crestline Management reported no remaining Adverum Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 6,485 Adverum Biotechnologies shares in Q3 2022, an estimated $78K.
  • Crestline Management first reported a position in Adverum Biotechnologies in Q1 2022 and held it in 2 quarters.
  • Crestline Management's Adverum Biotechnologies position peaked at $86K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.